Abstract. Endometrial cancer (EC) is a common form of cancer in women. Metastasis is the main cause of EC treatment failure. Eukaryotic translation initiation factor 4E (eIF4E) is an oncogene that is overexpressed in a variety of malignancies and their distant metastases. The present study analyzed microarray data from the Oncomine database and revealed that high eIF4E expression was associated with poor prognosis and high pathological grade of EC. The expression of eIF4E was higher in EC tissues compared with adjacent normal tissues. In addition, microRNA (miR)-320a and miR-340-5p expression levels were downregulated in EC tissues compared with those in adjacent normal tissues, which suggested that these microRNAs may serve as EC tumor suppressor genes. miR-320a and miR-340-5p could bind to the 3'-UTR of eIF4E mRNA, thus downregulating the expression of eIF4E and phosphorylated (p)-eIF4E in EC cells. Overexpression of miR-320a or miR-340-5p effectively suppressed HEC-1A cell migration and invasion. The downregulation of eIF4E and p-eIF4E following miR-320a or miR-340-5p transfection reduced the invasiveness and metastatic capability of EC cells in a manner associated with decreased expression of matrix metalloproteinase (MMP)-3 and MMP-9. In addition, one of the effects of transforming growth factor β1 (TGF-β1), which is to induce the phosphorylation of eIF4E, was suppressed by miR-320a and miR-340-5p overexpression. These two microRNAs also attenuated the features of TGF-β1-induced epithelial-mesenchymal transition (EMT). In conclusion, the results of the present study demonstrated that eIF4E was upregulated in EC, whereas miR-320a and miR-340-5p were downregulated in EC compared with adjacent normal tissues. In vitro, miR-320a and miR-340-5p inhibited the migratory capability of EC cells by downregulating MMP-3 and MMP-9 and prevented TGF-β1-induced EMT through p-eIF4E.

Introduction

Endometrial cancer (EC) is the most common malignancy of the female reproductive system, causing 76,000 deaths every year worldwide (1). Despite major advances in EC diagnosis and treatment strategies, metastasis is a significant clinical challenge and represents the main cause of EC mortality; in patients with EC without metastatic disease, the 5-year overall survival ranges between 74 and 91% (2), whereas patients with stage III or IV EC exhibit 5-year overall survival rates of 57-65 and 20-26%, respectively (1). Thus, understanding the underlying mechanisms of metastatic disease may help in the development of more effective therapeutic strategies for EC.

Eukaryotic translation initiation factor 4E (eIF4E) is the most important component of the eukaryotic translation initiation complex eIF4F. At the initiation of translation, eIF4E binds to the 5'-7-methylguanosine cap structure of an mRNA, connects it to the ribosome and enables translation (3). In addition to cap-dependent protein synthesis, eIF4E also contributes to malignancy as mRNAs regulated by eIF4E generally encode key proteins involved in cell proliferation, angiogenesis, survival and malignant transformation [e.g. cyclin D1, c-MYC, vascular endothelial growth factor and matrix metalloproteinase 9 (MMP-9)] (4). As an oncogene, eIF4E has been demonstrated to be upregulated in a variety of malignancies, such as breast (5), colorectal (6) and prostate (4).
cancer, but its role in EC remains to be elucidated. A previous study has revealed that eIF4E is more frequently upregulated in EC extending outside the uterus (FIGO stage III/IV vs. I/II, and downregulation of eIF4E by small interfering (si)RNA significantly reduced the proliferation of HEC-1A cells (7). These findings suggested that eIF4E may serve an important role in the metastasis of EC and may represent a potential anti-metastatic therapeutic target.

The epithelial-mesenchymal transition (EMT) is an important mechanism in tumor metastasis that is triggered by the activation of transcription factors such as Snail family transcriptional repressor 1 (Snail), Twist-related protein 1, Snail family transcriptional repressor 2, forkhead box C2, SOX4 and zinc finger E-box-binding homeobox (8). These activated transcription factors downregulate the epithelial marker E-cadherin, as well as polarity-related proteins, such as lethal giant larvae 2 (9,10), and upregulate mesenchymal markers such as N-cadherin and vimentin (11). The transcriptional events controlling EMT are well characterized, but the associated post-transcriptional mechanisms have not been clearly elucidated (12). A previous study has demonstrated that phosphorylation of eIF4E promotes transforming growth factor β1 (TGF-β1)-mediated EMT via Snail and MMP-3 translation activation of (9), suggesting that eIF4E may serve an important role in the translational control of EMT.

MicroRNAs (miRNAs) are an abundant class of small regulatory RNAs in animals and plants that serve important regulatory roles by interacting with the 3'-untranslated region (3'-UTR) of target mRNAs for cleavage or translational repression (13). A number of studies have demonstrated that miRNAs serve important roles in cell proliferation, apoptosis, migration, chemosensitivity and radio-resistance (14-18), and recent findings have revealed that miRNAs also regulate EMT in various tumor cells. In hepatocellular carcinoma, miRNA (miR)-199b-5p attenuates TGF-β1-induced EMT by directly targeting N-cadherin (19), whereas miR-190 suppresses TGF-β1-induced EMT by targeting SMAD2 in breast cancer (20). Although several miRNAs have been demonstrated to regulate EMT and metastasis of EC, the roles of miR-320a and miR-340-5p in EC have not yet been fully elucidated.

The present study aimed to investigate the expression of eIF4E, miR-320a and miR-340-5p in EC and identify their interactions. The effects of miR-320a and miR-340-5p on cell metastatic potential and EMT were further investigated in EC cells.

Materials and methods

eIF4E gene expression data from patients with EC in the Oncomine database. The Oncomine database (https://www.oncomine.org/resource/login.html) was used to mine the data of eIF4E gene expression in EC using the key words ‘eIF4E’ and ‘endometrial carcinoma’. For the Kaplan-Meier survival analysis, patients with eIF4E expression values below the 20th percentile were classified as having low eIF4E levels.

Endometrial cancer tissues. Between August 2016 and July 2017, eight pairs of EC and adjacent normal tissues (≥2 cm from the tumor edge), were collected from eight patients who underwent hysterectomy at the Affiliated Hospital of Binzhou Medical University. All samples were diagnosed by surgical-pathology or biopsy. The tissues were snap-frozen in liquid nitrogen and stored at -80°C for later experiments, including RNA extraction and western blotting. This study was approved by the Medical Ethics Committee of Binzhou Medical University (approval no. 2016-21). Informed consent was obtained from all patients prior to the collection of samples.

Cell culture. The human EC cell line HEC-1A was purchased from the Shanghai Institute of Cell Biology. The human EC cell lines Ishikawa and RL95-2 were obtained from Dalian Medical University. HEC-1A, RL-952 and Ishikawa cells were cultured in McCoy's 5A (Beijing Macgene Biotechnology Co., Ltd.), DMEM/F12 (Gibco; Thermo Fisher Scientific, Inc.) and RPMI-1640 (Gibco; Thermo Fisher Scientific, Inc.) medium, respectively. The media were supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) and 100 U/ml penicillin-streptomycin (Sigma-Aldrich; Merck KGaA) at 37°C with 5% CO₂ and saturated humidity.

miRNA transfections. EC cells (HEC-1A and RL95-2) at the logarithmic growth phase were seeded in 6-well plates at 3x10⁵ cells/well. Transfection was performed in triplicate at 50-60% confluency using 1 μg miRNA mimics, mutation mimics (mu-320a or mu-340-5p), siRNA or an eIF4E-encoding vector (Sino Biological, Inc.) in 2.5 µl Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). The sequences of the miRNA mimics were as follows: miR-320a sense, 5'-AAA AGCGUGGUUGAGGGCG-3' and antisense, 5'-GCCCU CUCACCCAGCUUUUU-3'; miR-340-5p sense, 5'-UAA GAACUGAGAGCAGUUU-3' and antisense, 5'-GCAUCAGU UCAUGCUUUAAAUU-3'. The mimics were synthesized by Shanghai GenePharma Co., Ltd. The sequences of si-eIF4E were sense, 5'-GCUCUUGCAGUUCUAACUAAU-3' and antisense, 5'-UGAUGAUAGAAUACAGACCUU-3', synthesized by Shanghai GeneChem Co., Ltd. Transfection was performed according to the manufacturer's instructions at room temperature; the transfection complex were replaced with complete medium 6-8 h post-transfection, and the cells were incubated for 24-48 h at 37°C prior to subsequent experiments. For experiments involving TGF-β1 treatment, various concentrations of TGF-β1 (5, 10 and 20 ng/ml; Sino Biological, Inc.) were added to treat EC cells for 48 h.

Reverse transcription-quantitative PCR (RT-qPCR). Total miRNA of endometrial adenocarcinoma cells (HEC-1A and RL95-2) was isolated by RNAiso Plus (Takara Bio, Inc.), and polyA was added using a polyA polymerase (Ambion; Thermo Fisher Scientific, Inc.). cDNA was synthesized using PrimeScriptÔ RT reagent Kit with gDNA Eraser (Takara Bio, Inc.) with the RT primer 5'-AACATCTGACGTCCATGGATG d(T)30N(A, G, C or T)-3' at 42˚C for 15 min, and qPCR was performed to detect miR-320a and miR-340-5p. Primers used for amplification were as follows: miR-320a forward, 5'-AAA AGCTGGGTGAGGAGG-3' and reverse, 5'-AATCGTATG AGTCCATGGATG-3'; miR-340-5p forward, 5'-AAGCAGATAGACTGATT-3' and reverse, 5'-AATCGTACATGCC TGGATG-3'; human 5S rRNA forward, 5'-GCCATAACACC
HEC-1A or RL-952 cells were subjected to an in vitro wound-healing assay; a sterile 10 µl pipette tip was used to scratch the confluent cell monolayer. The cells were washed, suspended in PBS and incubated in serum-free McCoy's 5A medium at 37°C. Images were captured using an inverted light microscope (x100 magnification; Leica Microsystems GmbH) at 0, 24 and 48 h of incubation. The rate of migration was measured by quantifying the distance that the HEC-1A cells moved from the edge of the scratch toward the center of the scratch (marked by dotted lines).

Transwell cell migration assays. HEC-1A or RL-952 cells were treated with miRNA mimics for 24 h. A total of 100 µl cell suspension was added to the upper chamber of the Transwell insert (Corning, Inc.) at a concentration of 5x10^5 cells/ml diluted with serum-free McCoy's 5A medium, whereas medium with 20% fetal calf serum was added to the lower chamber. At 24 h, the liquid in the upper chamber was removed, the surface was washed with PBS, the non-migrated cells were removed with a cotton swab, 600 µl 4% methanol was added to fix the cells (20 min at room temperature), and 600 µl 0.1% crystal violet (Sigma-Aldrich; Merck KGaA) was added to stain the cells (20 sec, annealing at 56°C for 20 sec and an extension at 72°C for 20 sec. Fluorescence was detected at 585 nm, and the cycle threshold (Ct) was recorded. Human 5S rRNA served as a control. The relative expression of miR-320a and miR-340-5p was normalized to that of 5S rRNA, and the experiments were repeated three times in triplicate. The results were quantified using the 2^(-ΔΔCq) method (21).

Wound-healing assay. HEC-1A cells were seeded into 12-well plates at 1.5x10^5 cells/well and cultured to 90% confluency the next day. Subsequently, these cells were subjected to the scratch (marked by dotted lines). A sterile 10 µl pipette tip was used to scratch the confluent cell monolayer, the cells were washed, suspended in PBS and incubated in serum-free McCoy's 5A medium at 37°C. Images were captured using an inverted light microscope (x100 magnification; Leica Microsystems GmbH) at 0, 24 and 48 h of incubation. The rate of migration was measured by quantifying the distance that the HEC-1A cells moved from the edge of the scratch toward the center of the scratch (marked by dotted lines).

Detection of apoptosis. Apoptosis was measured by fluorescence-activated cell sorting (FACS). Cells (HEC-1A and RL95-2) were cultured in 6-well plates at 3x10^5 cells/well and treated with miRNA mimics or control oligomers when the confluency reached 70% the next day. Detection of apoptosis was performed at 48 h using an Annexin V-FITC/PI apoptosis detection kit (BD Biosciences) according to the manufacturer's instructions. The cells were analyzed using a flow cytometer (Beckman Coulter, Inc.), and the CytoExpert 1.2.11.0 software (Beckman Coulter, Inc.) was used for data analysis.

Construction of the pcDNA-GFP-eIF4E-3'UTR vector. The sequence of the eIF4E 3'-UTR was obtained from GenBank and was amplified by PCR from human genomic DNA (extracted from whole human blood). The primer sequences were as follows: eIF4E 3'-UTR forward, 5'-CCCAAGCTT TCATTGCCCTTTGTTCTGTA-3' and reverse, 5'-CGGGTTCACCTGGCAAGGTGCTTTGATGC-3'. The eIF4E 3'-UTR was then inserted into a pcDNA3.1-GFP-neo (+) (GenScript Biotech, Inc.) expression vector.

Western blotting. Cells (HEC-1A or RL95-2) were lysed with RIPA lysis buffer containing a protease inhibitor cocktail (cat. no. S8820; Sigma-Aldrich; Merck KGaA) for 30 min on ice. The protein concentrations were measured using the bicinchoninic acid assay, and the protein (35 µg/lane) was subjected to SDS-PAGE (10%) and transferred onto PVDF membranes. Subsequently, the membranes were blocked with 7% fat-free milk and were immunoblotted overnight at 4°C with antibodies against eIF4E (1:1,000; cat. no. BS3432), p-eIF4E (1:1,000; cat. no. BS5015), α-smooth muscle actin (α-SMA; 1:1,000; cat. no. BS7000; all from Biogot Technology Co., Ltd.), MMP-3 (1:400; cat. no. bs-0413R; Bioss), MMP-9 (1:400; cat. no. bs-4593R; Bioss), E-cadherin (1:1,000; cat. no. 20874-1-AP; Proteintech Group, Inc) and Snail (1:1,000; cat. no. 13099-1-AP; Proteintech Group, Inc.), GAPDH (1:3,000; cat. no. AP0063; Biogot Technology Co., Ltd.) as a control. Following washing with TBS + Tween-20 (0.1%), the membranes were incubated with horseradish peroxidase-labeled goat anti-rabbit IgG (1:5,000; cat. no. ZB-2301; Beijing Zhongshan Golden Bridge Technology Co., Ltd.) for the detection of primary antibodies. The membranes were visualized with ECL (Shanghai Novland Technology Co., Ltd.) for the detection of primary antibodies. The membranes were blocked with 7% fat-free milk and were immunoblotted overnight at 4°C with antibodies against eIF4E (1:1,000; cat. no. BS3432), p-eIF4E (1:1,000; cat. no. BS5015), α-smooth muscle actin (α-SMA; 1:1,000; cat. no. BS7000; all from Biogot Technology Co., Ltd.), MMP-3 (1:400; cat. no. bs-0413R; Bioss), MMP-9 (1:400; cat. no. bs-4593R; Bioss), E-cadherin (1:1,000; cat. no. Snail (1:1,000; cat. no. AP0063; Biogot Technology Co., Ltd.) as a control. Following washing with TBS + Tween-20 (0.1%), the membranes were incubated with horseradish peroxidase-labeled goat anti-rabbit IgG (1:5,000; cat. no. ZB-2301; Beijing Zhongshan Golden Bridge Technology Co., Ltd.) for the detection of primary antibodies. The membranes were visualized with ECL (Shanghai Novland Co., Ltd.), and images were captured using an automatic chemiluminescence image analysis system (Tanon Science and Technology Co., Ltd.). Densitometric analysis of the blots was performed using Gel Image System 4.2 software (Tanon Science and Technology Co., Ltd.).

miRNA prediction. The online miRNA analysis software TargetScan (http://www.targetscan.org/vert_72/) was used to identify the miRNAs with potential binding sites in the eIF4E 3'-UTR.

Statistical analysis. Statistical significance of experimental data was evaluated with GraphPad Prism 5 (GraphPad Software, Inc.). Quantitative results are presented as the mean ± standard deviation. Paired Student's t-test was used to compare two groups. Differences among three or more groups were compared using one-way ANOVA followed by a Tukey's test. Correlations were calculated with a Spearman rank test. Array data of eIF4E were obtained from the Oncomine database.
Results

*eIF4E* is upregulated in EC tissues and is associated with poor clinical outcomes, whereas *miR-320a* and *miR-340-5p* are downregulated in EC tissues. The expression profile of
eIF4E in human EC was investigated using patient datasets from the Oncomine database. Data analysis revealed that high eIF4E expression levels in EC tissues were associated with reduced overall survival (Fig. 1A) and a high pathological grade (Fig. 1B). To validate this result, eIF4E protein expression was determined in eight pairs of EC and normal adjacent tissues by Western blotting. The results demonstrated that eIF4E expression levels in EC tissues were significantly higher compared with those in normal adjacent tissues (Fig. 1C and D). To explore their potential role in EC, the levels of miR-320a and miR-340-5p were measured by RT-qPCR in eight paired EC and adjacent tissues. Of note, miR-320a and miR-340-5p expression levels were significantly decreased in EC tissues compared with those in adjacent normal tissues (Fig. 1E and F). Correlation analysis indicated that the expression levels of miR-320a and miR-340-5p were inversely correlated with eIF4E expression (Fig. 1G and H). Collectively, these results suggested that eIF4E may function as a tumor promoter in EC.

eIF4E is overexpressed, whereas miR-320a and miR-340-5p are downregulated in HEC-1A and RL95-2 EC cell lines. eIF4E expression was analyzed by western blotting in three endometrial cancer cell lines: HEC-1A, Ishikawa and RL95-2 cells. The expression of eIF4E was high in HEC-1A and RL95-2 cells, but low in Ishikawa cells (Fig. 2A and B). The expression levels of miR-320a and miR-340-5p in the three human EC cell lines were measured by RT-qPCR; miR-320a and miR-340-5p were downregulated in HEC-1A and RL95-2 compared with Ishikawa cells (Fig. 2C and D). Based on these results, it was hypothesized that this heterogeneity was due to the degree of differentiation in the three cell lines.

eIF4E is a direct target of miR-320a and miR-340-5p. To investigate whether miR-320a and miR-340-5p were involved in regulating eIF4E expression, the potential miRNAs that target the 3'-UTR of eIF4E mRNA were determined. Based on the results of the online miRNA analysis software TargetScan, target sites for miR-320a and miR-340-5p were identified in the 3'-UTR of eIF4E (Fig. 3A). Treatment of HEC-1A cells with miR-320a or miR-340-5p mimics significantly increased their corresponding miRNA levels, as determined by RT-qPCR (Fig. 3B). Subsequently, a pcDNA expression vector encoding GFP-eIF4E-3'-UTR was co-transfected with miR-320a or miR-340-5p mimics into HEC-1A cells. Fluorescence microscopy revealed that the fluorescence intensity was significantly decreased in miR-320a and miR-340-5p mimic-treated cells.
compared with that in controls (Fig. 3C). Flow cytometry also demonstrated that the fluorescence decreased significantly in miR-320a and miR-340-5p mimic-treated cultures compared with that in the control groups (Fig. 3D). Western blotting confirmed that miR-320a and miR-340-5p mimics reduced the protein expression levels of not only eIF4E, but also p-eIF4E in HEC-1A cells (Fig. 4A-D). These experiments were repeated in RL95-2 cells, which confirmed the results obtained in HEC-1A cells (Fig. 4E-H). These results indicated that the eIF4E-3'UTR was directly targeted by miR-320a and miR-340-5p.

**Overexpression of miR-320a or miR-340-5p inhibits EC cell viability and migration.** Considering that high expression of eIF4E is associated with the prognosis and grade of EC, the present study investigated whether miR-320a and miR-340-5p may reduce the metastatic capability of EC cells. Either miR-320a or miR-340-5p mimic treatment in HEC-1A cells reduced the number of cells that migrated to the lower chamber in the Transwell assay; however, no effect was observed in RL95-2 cells (Fig. 5A-D). The results of the wound-healing assay also demonstrated that miR-320a or miR-340-5p mimics significantly decreased the migration in HEC-1A cells (Fig. 5E and F).

To further investigate the proliferation inhibitory effect of miR-320a and miR-340-5p in EC cells, MTT and apoptosis detection assays were performed. miR-320a and miR-340-5p mimics inhibited RL95-2 cell proliferation, but did not affect HEC-1A cells (Fig. 5G and H). In addition, flow cytometric analysis of apoptosis indicated that miR-320a and miR-340-5p mimics induced apoptosis in RL95-2 cells, but had no effect on apoptosis in HEC-1A cells (Fig. 5I and J).

**miR-320a and miR-340-5p mimics suppress MMP-3 and MMP-9 expression in HEC-1A cells.** MMP-3 and MMP-9 expression levels were determined to explore the mechanisms involved in reduced cell migration and invasion following either miR-320a or miR-340-5p mimic treatment. As demonstrated in Fig. 6, MMP-3 and MMP-9 protein levels were attenuated, suggesting that the reduced level of MMP-3 and MMP-9 following miR-320a or miR-340-5p mimic treatment may account, at least in part, for the anti-migratory effects of miR-320a and miR-340-5p mimics.

miR-320a and miR-340-5p mimics suppress TGF-β1-induced EMT and change p-eIF4E expression in EC cells. HEC-1A cells were treated with different concentrations of TGF-β1.
Figure 4. miR-320a and miR-340-5p mimics regulate the expression of eIF4E and p-eIF4E. (A and B) eIF4E and p-eIF4E levels were decreased in miR-320a-transfected HEC-1A cells. (C and D) eIF4E and p-eIF4E expression levels were decreased in miR-340-5p-transfected HEC-1A cells. (E and F) eIF4E and p-eIF4E levels were decreased in miR-320a mimic-transfected RL95-2 cells. (G and H) eIF4E and p-eIF4E expression levels were decreased in miR-340-5p mimic-transfected RL95-2 cells compared with the control. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. eIF4E, eukaryotic translation initiation factor 4E; miR, microRNA; negative, mock transfections; scrambled, cells treated with scrambled control miRNA mimics; miR-320a or miR-340-5p, cells treated with miR-320a or miR-340-5p mimics; mu-320a or mu-340-5p, cells treated with mutation sequence of mutant-miR-320a or mutant-miR-340-5p; siRNA-eIF4E, small interfering RNA targeting eIF4E.
miR-320a and miR-340-5p mimics regulate HEC-1A cell viability and migration. (A) Treatment with miR-320a or miR-340-5p mimics reduced HEC-1A migration determined by Transwell assay. (B) Quantitative analysis of the migration rates in (A). (C) Treatment with miR-320a or miR-340-5p mimics did not affect RL95-2 migration determined by Transwell assays. (D) Quantitative analysis of the migratory rates in (C). (E) The migratory ability of HEC-1A cells transfected with miR-320a and miR-340-5p mimics was detected by wound-healing assay. (F) Quantitative analysis of the wound closure ratios in (E). (G) HEC-1A cell proliferation according to the MTT assay. (H) RL95-2 cell proliferation according to the MTT assay; the OD at 490 nm was lower in either the miR-320a or miR-340-5p mimic-treated RL95-2 cells compared with that in the negative, scrambled or mutant control groups. (I) Flow cytometry analysis of either miR-320a or miR-340-5p mimic-induced apoptosis in HEC-1A cells. (J) Flow cytometry analysis of either miR-320a or miR-340-5p mimic-induced late apoptosis in RL95-2 cells. The number of apoptotic cells was increased in miR-320a- or miR-340-5p mimic-treated cells compared with those in the negative, scrambled or mutant control groups. ****P<0.0001; NS, no significant difference. miR, microRNA; negative, mock transfections; scrambled, cells treated with scrambled-oligomer control RNA; miR-320a or miR-340-5p, cells treated with miR-320a or miR-340-5p mimics; mu-320a or mu-340-5p, cells treated with mutated sequences of miR-320a or miR-340-5p; OD, optical density.
The expression of p-eIF4E was significantly enhanced by 10 ng/ml TGF-β1 (Fig. 7A-C), but this upregulation was suppressed when the cells were treated with miR-320a or miR-340-5p mimics (Fig. 7D-F). In terms of cell morphology, following 10 ng/ml TGF-β1 treatment for 48 h, HEC-1A cells exhibited fibroblast-like features; by contrast, a cobblestone-like appearance was observed in the control, miR-320a mimic + TGF-β1 and miR-340-5p mimic + TGF-β1 groups (Fig. 7G). An eIF4E-encoding vector co-transfected with either miR-320a or miR-340-5p into HEC-1A cells blocked the effects of miR-320a and miR-340-5p mimics on cell morphology (Fig. 7G).

To further explore the effects of miR-320a and miR-340-5p on the biological outcomes of EMT in HEC-1A cells, a wound-healing assay was performed; TGF-β1 promoted EC cell migration, whereas treatment with either miR-320a or miR-340-5p mimics prevented TGF-β1-induced cell migration (Fig. 7H and I).

**Discussion**

EC is the most common type of female reproductive system cancer and accounts for 4.8% of all cancers diagnosed in women (1). The mechanisms underlying metastasis, which is the main cause of EC treatment failure, have not been elucidated. Thus, a clearer understanding of metastasis is critical for the development of new therapeutic strategies for treating EC.

The miRNA-mediated regulation has complex cellular outcomes, as miRNAs can be involved in cell proliferation, apoptosis, invasion and migration (22,23). First identified as a potential modulator of aquaporin 1 and aquaporin 4, miR-320a also serves a role in cerebral ischemia (24). In metastatic colon cancer tissues and cells within the liver, miR-320a

---

**Figure 6.** miR-320a and miR-340-5p mimic treatment suppresses the expression of MMP-3 and MMP-9 in HEC-1A cells. (A) Western blotting analysis indicated that the expression levels of MMP-3 and MMP-9 were downregulated following miR-320a or miR-340-5p mimic treatment. (B-E) Quantification of (B) MMP-3, (C) MMP-9, (D) p-eIF4E and (E) eIF4E relative expression levels (n=3). *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. eIF4E, eukaryotic translation initiation factor 4E; p, phosphorylated; miR, microRNA; MMP, matrix metalloproteinase; negative, mock transfections; scrambled, cells treated with scrambled-oligomer control RNA; miR-320a or miR-340-5p, cells treated with miR-320a or miR-340-5p mimics.
miR-320a and miR-340-5p are miRNAs that are associated with various cancer types. miR-320a is downregulated in colorectal cancer and inhibits cell proliferation by targeting β-catenin. In non-small cell lung cancer, miR-320a suppresses cell migration and invasion through the PI3K/Akt signaling pathway. Another miRNA, miR-340-5p, is downregulated in cervical cancer and inhibits cancer metastasis by targeting Ephrin type-A receptor 3. In breast cancer, miR-340-5p inhibits proliferation and drug resistance by regulating the expression of leucine-rich repeat-containing G protein-coupled receptor 5 via the Wnt/β-catenin pathway. In the present study, miR-320a and miR-340-5p expression levels were downregulated in endometrial cancer tissues, and miR-320a or miR-340-5p mimics inhibited the migration and invasion of EC cells in vitro.
downregulating eIF4E. In addition, miR-320a and miR-340-5p mimics exhibited different effects on different EC cell lines; HEC-1A migration was significantly affected by miR-320a or miR-340-5p, whereas RL95-2 cell migration was not. By contrast, miR-320a or miR-340-5p mimics exhibited effects on RL95-2 cell proliferation and apoptosis, which may have been a result of the different degrees of differentiation and different phenotypic characteristics of the two EC cell lines. Upregulation of eIF4E, a translation initiation factor, has been previously detected in many human tumors. Specifically, eIF4E has been associated with disease progression, cellular transformation, tumorigenesis and metastasis in experimental models (29). Choi et al (7) first reported that the positive rate of eIF4E expression is higher in metastatic EC and promotes the proliferation of HEC-1A cells in vitro. Additionally, another study demonstrated that eIF4E levels were higher in EC specimens compared with those in hyperplastic or normal endometrial tissue specimens (30). In the present study, analysis of the Oncomine database revealed that high eIF4E expression was associated with a poor prognosis and a high pathological grade of EC.

The results of the present study demonstrated that either miR-320a or miR-340-5p mimics downregulated the expression levels of MMP-3 and MMP-9 by targeting eIF4E. MMP-3 has been reported to be involved in vascular invasion and metastasis of EC through EMT (31). The translation of MMP-9 mRNA has been demonstrated to be exceptionally dependent on elevated eIF4F activity (32). MMP-9 is a target of eIF4E, and its upregulation is associated with vascular and lymphatic invasion in EC (33). Considering the results of the present study, it may be hypothesized that the inhibition of MMP-3 and MMP-9 expression may represent one of the mechanisms by which miR-320 and miR-340-5p prevent the invasion and migration of EC cells. This process may also be related to other mechanisms; in EMT, benign tumor cells acquire the capacity of invasion and metastasis and can infiltrate the surrounding tissues and eventually move to distant regions (34). During EMT and tumor invasion, eIF4E has been identified to serve important roles, as it has been demonstrated to regulate the expression of a number of proteins involved in EMT and metastasis, such as MMP-3 and Snail (35). Smith et al (9) demonstrated that
overexpression of eIF4E induced EMT in lung epithelial cells. TGF-β is a major regulator of the EMT (34). In the present study, exogenous TGF-β1-induced EMT of HEC-1A cells was accompanied by a upregulation of p-eIF4E. These results suggested that eIF4E may promote a metastatic phenotype of EC, in part by regulating EMT. It was thus predicted that suppression of eIF4E may inhibit EMT in EC; transfection with either miR-320a or miR-340-5p mimics in EC cells prevented TGF-β1-induced changes in cell morphology and the upregulation of p-eIF4E. In addition, the expression of Snail was attenuated by miR-320a and miR-340-5p mimics. Snail, which is a key regulator of EMT, induces epithelial cells with migratory and invasive properties during tumor progression (36), and several studies have confirmed that Snail stimulates invasion and metastasis of EC (37,38). Robichaud et al (35) have demonstrated that Snail is regulated by p-eIF4E. The results of the present study demonstrated that downregulation of Snail by either miR-320a/p-eIF4E or miR-340-5p/p-eIF4E may represent a part of the mechanism underlying the prevention of TGF-β1-induced EMT. In addition, the TGF-β1-induced downregulation of E-cadherin and upregulation of α-SMA were prevented in miR-320a or miR-340-5p mimic-treated cells.
In conclusion, the results of the present study demonstrated that in EC, eIF4E was upregulated, whereas miR-320a and miR-340-5p were downregulated. Specifically, miR-320a and miR-340-5p mimics inhibited the proliferation and migration of EC cells in vitro by downregulating MMP-3 and MMP-9 expression and prevented the TGF-β1-induced EMT by targeting p-eIF4E. These results suggested that miR-320a and miR-340-5p may be potential therapeutic targets for EC treatment.

Acknowledgements

Not applicable.

Funding

This study was supported by National Natural Scientific Grants (grant no. 31570798 and 31970798), National Natural Science Foundation of China (grant no. LR2017042), Liaoning Excellent Talents Program in University (grant no. 31570798 and 31970798), Liaoning Excellent Talents in Medicine (grant no. LR2017042), and National Natural Science Foundation of China (grant no. 31871209). This study was supported by National Natural Scientific Grants (grant no. LR2017042), Liaoning Provincial Talent Project, and the Shandong Science and Technology Committee (grant no. 2018GSF118056).

Availability of data and materials

The datasets used or analyzed in the present study are available from the corresponding author upon reasonable request.

Authors’ contributions

HHZ and YK analyzed the data and wrote the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All experiments with human specimens were performed in accordance with the relevant guidelines and were approved by the Medical Ethics Committee of Binzhou Medical University (Yantai, China). Prior to study inclusion, written informed consent was obtained from all patients.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Van Nyen T, Moiola CP, Colas E, Annibali D and Amant F: Modeling endometrial cancer: Past, present, and future. Int J Mol Sci 19: E32348, 2018.
2. Morice P, Leary A, Creutzberg C, Abu-Rustum N and Darai E: Endometrial cancer. Lancet 387: 1094-1108, 2016.
3. Jackson RJ, Hellen CU and Pestova TV: The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol 11: 113-127, 2010.
4. De Benedetti A and Graff JR: eIF-4E expression and its role in malignancies and metastases. Oncogene 23: 3189-3199, 2004.
5. Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, Retrouvey H, Puckett R, Flores LM, Krop IE, Rousseau C, Cocolakis E, et al.: Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clin Cancer Res 17: 2874-2884, 2011.
6. Berkel HJ, Turbat-Herrera EA, Shi R and de Benedetti A: Expression of the translation initiation factor eIF4E in the poly-p-cancer sequence in the colon. Cancer Epidemiol Biomarkers Prev 10: 663-666, 2001.
7. Choi CH, Lee JS, Kim SR, Lee YY, Kim CJ, Lee JW, Kim TJ, Lee JH, Kim BG and Bae DS: Direct inhibition of eIF4E reduced cell growth in endometrial adenocarcinoma. J Cancer Res Clin Oncol 137: 463-469, 2011.
8. Zheng H and Kang Y: Multilayer control of the EMT master regulators. Oncogene 33: 1755-1763, 2014.
9. Smith KA, Zhou B, Avdulov S, Benyumov A, Peterson M, Liu Y, Okon A, Hergert P, Braziunas J, Wagner CR, et al.: Transforming growth factor-β1 induced epithelial mesenchymal transition is blocked by a chemical antagonist of translation factor eIF4E. Sci Rep 5: 18233, 2015.
10. Spaderna S, Schmalhofer O, Wahlbuhl M, Dimmler A, Bauer K, Sultan A, Hlabek F, Jung A, Strand D, Eger A, et al.: The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 68: 537-547, 2008.
11. Li Y, Xie Y, Cui D, Ma Y, Sui L, Zhu C, Kong K and Hong Y: Osteopontin promotes invasion, migration and epithelial-mesenchymal transition of human endometrial carcinoma cell HEC-1A through AKT and ERK1/2 signaling. Cell Physiol Biochem 37: 1503-1512, 2015.
12. Aparicio LA, Abella V, Valladares M and Figueroa A: Posttranscriptional regulation by RNA-binding proteins during epithelial-to-mesenchymal transition. Cell Mol Life Sci 70: 4463-4477, 2013.
13. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
14. He M and Xue Y: MicroRNA-148a suppresses proliferation and invasion potential of non-small cell lung carcinomas via regulation of STAT3. Onco Targets Ther 10: 1353-1361, 2017.
15. Zhang HH, Fang M, Dong W, Xin JX, Li YJ, Zhang ZC, Yu L, Wang PY, Li BS and Xie SY: miR-511 induces the apoptosis of radiosensitive lung adenocarcinoma cells by triggering BAX. Oncol Rep 31: 1473-1479, 2014.
16. Zhao W, Sun Q, Yu Z, Mao S, Jin Y, Li J, Jiang Z, Zhang Y, Chen M, Chen P, et al.: MiR-320a-3p/ELF3 axis regulates cell metastasis and invasion in non-small cell lung cancer via PI3K/Akt pathway. Gene 670: 31-37, 2018.
17. Ge X, Cui H, Zhou Y, Yin D, Feng Y, Xin Q, Xu X, Liu W, Liu S and Zhang Q: miR-320a modulates cell growth and chemosensitivity via regulating ADAM10 in gastric cancer. Mol Med Rep 16: 9664-9670, 2017.
18. Wu X, Tang H, Liu G, Wang H, Shu J and Sun F: miR-448 suppressed gastric cancer proliferation and invasion by regulating ADAM10. Tumour Biol 37: 10545-10551, 2016.
19. Zhou SJ, Liu FY, Zhang AH, Liang HF, Wang Y, Ma R, Jiang YH and Sun NF: MicroRNA-199b-5p attenuates TGF-β1-induced epithelial-mesenchymal transition in hepatocellular carcinoma. Br J Cancer 117: 253-254, 2017.
20. Yu Y, Luo W, Yang ZJ, Chi JR, Li YR, Ding Y, Ge J, Wang X and Cao XC: miR-190 suppresses breast cancer metastasis by regulation of TGF-β1-induced epithelial-mesenchymal transition. Mol Cancer 17: 70, 2018.
21. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2ΔΔC(T) method. Methods 23: 402-408, 2001.
22. Cheng AM, Byrom MW, Shelton J and Ford LP: Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 33: 1290-1297, 2005.
23. Baranwal S and Alahari SK: miRNA control of tumor cell invasion and metastasis. Int J Cancer 126: 1283-1290, 2010.
24. Separamamian S, Armugam A, Lim KY, Karolina DS, Summanathan P, Tan IR and Jeyaseelan K: MicroRNA-320a functions as a novel endogenous modulator of aquaporins 1 and 4 as well as a potential therapeutic target in cerebral ischemia. J Biol Chem 285: 29223-29230, 2010.
25. Zhang Y, He X, Liu Y, Ye Y, Zhang H, He R, Zhang Q, Dong L, Liu L and Dong J: microRNA-320a inhibits tumor invasion by targeting neuropilin 1 and is associated with liver metastasis in colorectal cancer. Oncol Rep 27: 685-694, 2012.
26. Sun JY, Huang Y, Li JP, Zhang X, Wang L, Meng YL, Yan B, Bian YQ, Zhao J, Wang WZ, et al: MicroRNA-320a suppresses human colon cancer cell proliferation by directly targeting \(\beta\)-catenin. Biochem Biophys Res Commun 420: 787-792, 2012.

27. Xiao H, Yu L, Li F, Wang H, Li W and He X: MiR-340 suppresses the metastasis by targeting EphA3 in cervical cancer. Cell Biol Int 42: 1115-1123, 2018.

28. Shi S, Chen X, Liu H, Yu K, Bao Y, Chai J, Gao H and Zou L: LGR5 acts as a target of miR-340-5p in the suppression of cell progression and drug resistance in breast cancer via Wnt/\(\beta\)-catenin pathway. Gene 683: 47-53, 2019.

29. Graff JR, Konicek BW, Carter JH and Marcusson EG: Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 68: 631-634, 2008.

30. Shi ZM, Liu YN, Fu B, Shen YF and Li LM: Expression profile of eukaryotic translation initiation factor and matrix metalloproteinase 9 in endometrial cancer tissue. J Biol Regul Homeost Agents 31: 1053-1059, 2017.

31. Mannelqvist M, Stefansson IM, Bredholt G, Hellem Bo T, Oyan AM, Jonassen I, Kalland KH, Salvesen HB and Akslen LA: Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer. Am J Pathol 178: 861-871, 2011.

32. Konicek BW, Dumstorf CA and Graff JR: Targeting the eIF4F translation initiation complex for cancer therapy. Cell Cycle 7: 2466-2471, 2008.

33. Karahan N, Guney M, Baspinar S, Oral B, Kapucuoglu N and Mungan T: Expression of gelatinase (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma. Eur J Gynaecol Oncol 28: 184-188, 2007.

34. Lee JM, Dedhar S, Kalluri R and Thompson EW: The epithelial-mesenchymal transition: New insights in signaling, development, and disease. J Cell Biol 172: 973-981, 2006.

35. Robichaud N, del Rincon SV, Huor B, Alain T, Petruccelli LA, Hearnden J, Goncalves C, Grotegut S, Spruck CH, Furic L, et al: Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3. Oncogene 34: 2032-2042, 2015.

36. Vega S, Morales AV, Ocaña OH, Valdes F, Fabregat I and Nieto MA: Snail blocks the cell cycle and confers resistance to cell death. Genes Dev 18: 1131-1143, 2004.

37. Dragomirescu M, Stepan AE, Margaritescu Cand Simionescu CE: The immunooexpression of p53 and snail in endometrioid endometrial carcinomas. Rom J Morphol Embryol 59: 131-137, 2018.

38. Xiong S, Klausen C, Cheng JC and Leung PC: Activin B promotes endometrial cancer cell migration by down-regulating E-cadherin via SMAD-independent MEK-ERK1/2-SNAIL signaling. Oncotarget 7: 40060-40072, 2016.